Wagner Wealth Management (South Carolina)’s UroGen Pharma URGN Stock Holding History

Wagner Wealth Management (South Carolina)’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$5K	Buy	+102	New	+$4.74K	﹤0.01%	491

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Wagner Wealth Management (South Carolina)'s URGN Position: Q3 2018 in Review

Wagner Wealth Management (South Carolina) opened a new position in UroGen Pharma (URGN) in Q3 2018: 102 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #491 among its holdings.

71 funds tracked by Wall St. Rank hold URGN as of Q3 2018.

Wagner Wealth Management (South Carolina) held 102 shares of UroGen Pharma worth $5K as of Q3 2018.
UroGen Pharma was a new Wagner Wealth Management (South Carolina) position in Q3 2018.
UroGen Pharma made up ﹤0.01% of Wagner Wealth Management (South Carolina)'s portfolio in Q3 2018, its #491 holding.
71 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2018.

Based on Wagner Wealth Management (South Carolina)'s 13F filing for Q3 2018, filed 5 Nov 2018.